Viridian Therapeutics Inc. (NASDAQ:VRDN) reported positive Phase 1 clinical trial results for VRDN-008, highlighting its pharmacokinetic and pharmacodynamic profile as a potential best-in-class subcutaneous treatment for autoimmune and rare diseases.
The biotechnology company confirmed the investigational therapy sustained IgG antibody reduction through eight weeks, supporting a transformative dosing schedule of once every eight weeks for future patients.
• Viridian Therapeutics stock is showing exceptional strength. What’s behind VRDN gains?
Phase 1 Trial Highlights Extended Half-Life and IgG Suppression
The Phase 1 clinical study evaluated subcutaneous VRDN-008 in healthy volunteers who received two subcutaneous doses, one at trial initiation and a second dose at week four.
VRDN-008, a bifunctional FcRn inhibitor licensed from Paragon Therapeutics, integrates an Fc fragment with an albumin-binding domain to prolong antibody suppression.
Clinical findings showed VRDN-008 achieved an extended half-life of 15 to 18 days, lasting up to six times longer than first-generation Fc fragments.
The candidate produced deep and prolonged IgG suppression, achieving a 74% IgG reduction at peak levels across the eight-week post-dosing period.
VRDN-008 also demonstrated a favorable safety profile that spared albumin and LDL cholesterol, with healthy volunteers reporting no serious adverse events or dose-limiting toxicities during the study.
Wearable On-Body Device Enables At-Home Administration
Viridian plans to administer subcutaneous VRDN-008 using the Enable enFuse wearable delivery device developed by Enable Injections.
This hands-free, on-body injector operates with a single button press, representing the next generation of drug delivery to simplify at-home self-administration.
Viridian secured exclusive global rights to enFuse for FcRn-targeted therapies in January 2023.
Registrational Study Targets Mid-2027 Launch In MG
Encouraged by the Phase 1 outcomes, Viridian plans to advance VRDN-008 rapidly into pivotal development to establish a direct path toward a Biologics License Application.
Pending feedback from regulatory authorities, the company aims to initiate at least one registrational trial in mid-2027, starting with myasthenia gravis.
The multi-arm registrational trial will deliver VRDN-008 through the enFuse system and evaluate four-week and eight-week dosing regimens against placebo.
Viridian also plans to expand VRDN-008 development into multiple autoantibody-mediated autoimmune diseases beyond myasthenia gravis.
VRDN Price Action: Viridian Therapeutics shares were up 4.69% at $29.83 at the time of publication on Monday, according to Benzinga Pro data.
Image via Shutterstock
See More: Top Growth Stocks